Adaptive Biotechnologies' clonoSEQ MRD Test Featured in Record 89 Abstracts at ASH 2025
核心洞察
Adaptive Biotechnologies announced that its clonoSEQ (搜索) MRD test will be featured in 89 abstracts at the 67th ASH Annual Meeting, including 36 oral presentations.
The abstracts span multiple blood cancers including multiple myeloma (搜索), acute lymphoblastic leukemia (搜索), chronic lymphocytic leukemia (搜索), mantle cell lymphoma (搜索), and diffuse large B-cell lymphoma (搜索).
More than 17 presentations demonstrate how clonoSEQ (搜索) MRD assessment is informing patient treatment decisions in real-world clinical practice across various blood cancers.
Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ (搜索) test for measurable residual disease (MRD) assessment will be included in 89 abstracts at the 67th Annual Meeting of the American Society of Hematology (搜索) (ASH) taking place December 6-9, 2025, in Orlando. The record-setting presence includes 36 oral presentations, reflecting widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development.
Comprehensive Coverage Across Blood Cancers
The abstracts featuring clonoSEQ (搜索) MRD data span multiple myeloma (搜索) (MM), acute lymphoblastic leukemia (搜索) (ALL), chronic lymphocytic leukemia (搜索) (CLL), mantle cell lymphoma (搜索) (MCL), diffuse large B-cell lymphoma (搜索) (DLBCL), and other blood cancers. This breadth underscores clonoSEQ's position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies.
More than 17 presentations demonstrate how clonoSEQ (搜索) MRD assessment is informing patient treatment decisions in real-world clinical practice, including studies to guide treatment in ALL, CLL, MM, MCL and DLBCL. The continued expansion of clonoSEQ use in clinical trials enables the deepest assessment of treatment responses for novel regimens and across a wide range of therapeutic modalities, including CAR-T, bispecific antibodies, and other targeted therapies.
Clinical Impact and Industry Recognition
"It's energizing to see the breadth of ASH presentations incorporating clonoSEQ (搜索) this year, highlighting how integral MRD testing has become in patient care and clinical research across hematologic oncology," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "This momentum reflects the multifaceted role MRD is playing in modern lymphoid cancer care—from guiding treatment decisions to accelerating therapeutic innovation."
Regulatory Status and Technical Capabilities
clonoSEQ (搜索) is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (搜索) or B-cell acute lymphoblastic leukemia (搜索) using bone marrow, and in patients with chronic lymphocytic leukemia (搜索) using blood or bone marrow. The test is also available in diffuse large B-cell lymphoma (搜索), mantle cell lymphoma (搜索) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
The test identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ (搜索) is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR).